All In Biotech

Drug Trial Radar · NCT06128213

NRX-101 for Complicated Urinary Tract Infection (UTI) Including Pyelonephritis

An Open Label Study of NRX-101 for Patients With Acute Complicated Urinary Tract Infection Including Pyelonephritis

Last checked: Nov 19, 2026Latest source record: Nov 13, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

13

Planned (sponsor's estimate)

Start

Mar 31, 2024

Primary completion

Jun 30, 2024

Study completion Sep 30, 2024

Sponsor

Lead sponsor
NeuroRx, Inc.Industry
Sponsor type
Industry
First posted
Nov 13, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical study is to test NRX101 in participants with complicated urinary tract infections including pyelonephritis. The main questions it aims to answer are: * Does NRX101 help participants resolve UTIs? * Is NRX101 safe for participants with UTIs? Participants will be seen in a doctor's office approximately 6 times to: * Answer a short 10 item questionnaire. * Review of side effects * Urine tests * Blood draw (about 10 ml or 2 teaspoons) * Review of medications * Review any signs or symptoms of UTI * Vital signs and weight (including blood pressure, heart rate, respiratory rate, and temperature) * Review of medical history This is an open-label study of NRX101, which means both you and your doctor know what drug you are taking. After the study is completed, researchers will look at the data to see if NRX101 helps participants with complicated UTI's.

Conditions

  • Urinary Tract Infections
  • Pyelonephritis

Interventions

  • NRX101 (a fixed dose combination of D-cycloserine (DCS) and lurasidone HCl (lurasidone))Drug

    oral NRX-101 (a fixed dose combination of 487.5 mg D-cycloserine (DCS) and 16.5 mg lurasidone HCl (lurasidone) twice daily for 10 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Microbiologic ResponseTime frame: Day 14

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.